Vance Garrison Fowler M.D.  Duke University School of Medicine   link

• 13:00 – What antibiotics do you give someone who has e-coli in the blood?
• 17:20 – We have no good treatment for devices (prosthesis or pacemaker)
• 17:30 – If you have a device that has an infection, you need to take out the device
• 17:50 – The cost associated with device removal and replacement is b/w $80-100K
• 36:00 – The Contrafect Phase 2 study ‘was a robust study. These are data you should be able to bank on b/c the quality of the study.’
• 40:15 – ‘We need new treatment’ for Staph bacteremia

Cara Cassino M.D.  (ContraFect CMO)

• 42:50 – study was a novel Phase2 superiority designed trial – very rare as unicorns
• 46:35 – FDA only has 2 approved agents to treat MRSA
• 48:50 – Day 180 – Exebacase did not appear to be sensitizing for allergic hypersensitivity – similar to Phase 1  should they be exposed to it in the future (they will not have a reaction when dosed a 2nd time)
• 51:30 – Daptomycin, Vancomycin – only 2 drugs to treat MRSA
• 52:00 – Exebacase was associated with consistently MRSA higher responder rates regardless the source of the infection
• 55:00 – Health economic signal – Exebacase reduced the median length of stay in Mrsa patients by 4 days ( 6 vs. 10)
• 56:50 – For all cause 30-day readmission rates for Staph (MRSA & MSSA), Exebacase reduced the rates essentially in half (16% vs. 31%)
• 1:01:30 – In summary Phase 2 study represents a landmark 1st step towards a brand new treatment paradigm for treating serious life-threatening antibiotic resistant infections. The first new step in decades. Exebacase is a first in class direct lycit agent with a completely new treatment modality – distinct from conventional antibiotics.

Dr. Ralph Corey – Duke Global Health Institute – Infectious Disease Expert  link

• 1:04:45 – What has been said today is astonishing from all aspects
• 1:05:30 – lists all the areas that MRSA affects/destroys (skin – okay, joints – not okay, heart valves – bad, spinal tissues – real bad)  They are the darth vaders of ____
• 1:06:00 – most people thing staph is soft tissue infections, but this perception is misguided
• 1:06:20 – Story of a male construction worker who scrapped his harm and the infection spread to his liver in the form of an abscess, which tested positive for MRSA. The Patient was in the hospital for 4 weeks.  5-day after completing the antibiotics he complained about a sudden onset of pain in his back. After enough MRI scans, they eventually found the problem – inflamed disc.  He was then treated for 6 weeks.
• 1:14:45 – I think the results of the phase 2 trial were fantastic. I didn’t expect it at all, and I have been on 30 trials.
• 1:16:25 – 8 different trials looking for a vaccine that prevented S. aureus…and they all failed
• 1:19:05 – I think this is huge for a lytic agent ‘to destroy a biofilm’. If you can do this the antibiotics can get to the bacteria more easily.
• 1:20:35 – I think we have a really, really good chance of making this (Exebacase) a key player of treating staph infection

Roger Pomerantz M.D. (ContraFect CEO)

• 1:30:25 – CEO came out of retirement 2x, helped bring 12 drugs to FDA approval
• 1:31:10 – I am excited To see 42% improvement is remarkable
• 1:31:30 – If we can repeat MRSA results in Phase 3, this does change the world
• 1:33:05 – $500M peak sales for MRSA in the US alone (stated in 2019)
• 1:35:20 – SOC in eastern Europe and Boston, MA are different
• 1:35:30 – To get the cleanest dataset, we will start in the US
• 1:36:05 – We want to make the trial as molecularly clean as possible to not have confounding variables.  We will figure out what other populations can use it separately.
• 1:36:20 – Phase 2 helped us figure out which are the syndromes you want to target.  We have that answer now.
• 1:37:15 – If Execabase does not succeed, the MRSA needle will not move for the next decade.
• 1:37:50 – A safe, easy to give drug that is not an antibiotic is something that…I am honored to be here and work with it.